At the time of writing, Kura Oncology Inc [KURA] stock is trading at $11.73, up 5.01%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The KURA shares have gain 8.11% over the last week, with a monthly amount glided 20.93%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, BTIG Research downgraded its rating to Neutral on February 06, 2025. On October 24, 2024, UBS initiated with a Buy rating and assigned a price target of $27 on the stock. Stifel downgraded its rating to a Hold and decreased its price target to $19 on October 14, 2024. Mizuho initiated its recommendation with a Buy and recommended $26 as its price target on December 22, 2023. BofA Securities started tracking with a Buy rating for this stock on August 11, 2023, and assigned it a price target of $31. In a note dated July 27, 2023, Scotiabank initiated an Sector Perform rating and provided a target price of $10.50 on this stock.
For the past year, the stock price of Kura Oncology Inc fluctuated between $5.41 and $12.49. Currently, Wall Street analysts expect the stock to reach $35.33 within the next 12 months. Kura Oncology Inc [NASDAQ: KURA] shares were valued at $11.73 at the most recent close of the market. An investor can expect a potential return of 201.19% based on the average KURA price forecast.
Analyzing the KURA fundamentals
Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at -2.31%, Pretax Profit Margin comes in at -2.06%, and Net Profit Margin reading is -2.08%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.65 and Total Capital is -0.45. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.34 points at the first support level, and at 10.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.98, and for the 2nd resistance point, it is at 12.23.
Ratios To Look Out For
It is important to note that Kura Oncology Inc [NASDAQ:KURA] has a current ratio of 5.12. Further, the Quick Ratio stands at 5.12, while the Cash Ratio is 0.79. Considering the valuation of this stock, the price to sales ratio is 9.81, the price to book ratio is 4.21.
Transactions by insiders
Recent insider trading involved Bair Teresa Brophy, Chief Legal Officer, that happened on Nov 14 ’25 when 8804.0 shares were sold. Chief Commercial Officer, Powl Brian T. completed a deal on Nov 14 ’25 to sell 8887.0 shares. Meanwhile, Chief Medical Officer Leoni Mollie sold 15485.0 shares on Nov 14 ’25.
